Nyrada Inc Significant Neuroprotection Achieved in Collaborative Traumatic Brain Injury Study

Highlights:
•Lead drug candidate NYR-BI03 shows strong neuroprotective efficacy in a penetrating traumatic brain injury study, conducted in collaboration with Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney.
•MRI imaging confirms statistically significant neuroprotection (p = 0.043), as assessed at UNSW Sydney.
•NYR-BI03 is currently in Phase I clinical trial, evaluating safety and tolerability. It is a first-in-class TRPC 3/6/7 blocker with a novel mechanism of action, targeting multiple high-value indications.